Treatment 0of bone metastases in urologic malignancies

Urologia Internationalis

Volumn 93, Issue 3, 2014, Pages 249-256

  Froehner, Michael ^a   Hölscher, Tobias ^a   Hakenberg, Oliver W ^b   Wirth, Manfred P ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Bone metastases; Denosumab; Radiotherapy; Stereotactic; Urologic neoplasms; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; DENOSUMAB; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

BLADDER CANCER; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL DISEASE; GERM CELL TUMOR; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MINIMAL RESIDUAL DISEASE; PALLIATIVE THERAPY; PENIS CANCER; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CHEMISTRY; MALE; METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; PROSTATIC NEOPLASMS; RADIOSURGERY; SECONDARY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CISPLATIN; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOSURGERY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84908653226     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000365788     Document Type: Review

References (41)

1. Poon M, Zeng L, Zhang L, Lam H, Emmenegger U, Wong E, Bedard G, Lao N, Chow R, Chow E: Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents. Clin Oncol (R Coll Radiol) 2013; 25: 435-444.
2. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K: New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013; 63: 309-320.
3. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C: Denosumab and bone-metastasisfree survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46.
4. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, Howell D, Konski A, Kachnic L, Lo S, Sahgal A, Silverman L, von Gunten C, Mendel E, Vassil A, Bruner DW, Hartsell W; American Society for Radiation Oncology (ASTRO): Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965-976.
5. Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK: Single versus multiple fractions of repeat radiation for painful bone metastases: A randomised, controlled, noninferiority trial. Lancet Oncol 2014; 15: 164-171.
6. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ: Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14: E28-e37.
7. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders PFA, Powles T, Staehler M, Volpe A: Guidelines on renal cell carcinoma. Update 2014. http://www.uroweb.org/gls/pdf/10%20 Renal%20Cell%20Carcinoma-LR.pdf (visited May 1, 2014).
8. Heidenreich A, Bastian PJ, Bellmunt J, Bolla N, Joniau S, Mason MD, Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. Update 2014. http://www.uroweb.org/gls/pdf/09-Prostate-Cancer-LR.pdf (visited May 1, 2014).
9. Deutsche Gesellschaft für Urologie e. V.: Konsultationsfassung 2014. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMFRegister- Nummer (034/022OL) Version 2.2 - 2. Aktualisierung 2014. http://www. dgu.de/fileadmin/MDB/PDF/konsultationsfassung- leitlinie-prostatakarzinom.pdf (visited May 1, 2014).
10. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline ® ): Prostate Cancer, Version 2.2014. http://www.nccn.org/professionals/physician-gls/pdf/prostate. pdf (visited May 1, 2014).
11. National Institute for Health and Care Excellence (NICE): NICE clinical guideline 58: Prostate cancer. Diagnosis and treatment. ht tp://www.nice.org.uk/nicemedia/live/11924/39687/39687.pdf (visited May 1, 2014).
12. American Urological Association: Guideline for the management of clinically localized prostate cancer: 2007 update (reviewed and validity confirmed 2011). http://www.auanet. org/common/pdf/education/clinicalguidance/Prostate-Cancer.pdf (visited July 30, 2014).
13. Tabata K, Niibe Y, Satoh T, Tsumura H, Ikeda M, Minamida S, Fujita T, Ishii D, Iwamura M, Hayakawa K, Baba S: Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulm Med 2012; 2012: 541656.
14. Cathomas R, Bajory Z, Bouzid M, El Ghoneimy A, Gillessen S, Goncalves F, Kacso G, Kramer G, Milecki P, Pacik D, Tantawy W, Lesniewski-Kmak K: Management of bone metastases in patients with castration-resistant prostate cancer. Urol Int 2014; 92: 377-386.
15. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P: Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: Deferring androgen deprivation therapy. Clin Genitourin Cancer 2013; 11: 27-32.
16. Bhattasali O, Chen LN, Tong M, Lei S, Collins BT, Krishnan P, Kalhorn C, Lynch JH, Suy S, Dritschilo A, Dawson NA, Collins SP: Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer. Front Oncol 2013; 3: 293.
17. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
18. Saad F: Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002; 1: 145-152.
19. Saad F, Chen YM, Gleason DM, Chin J: Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007; 5: 390-396.
20. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011; 377: 813-822.
21. Arzneimittelkommission der deutschen Ärzteschaft: Sicherheitsaspekte bei der Anwendung von Denosumab (Prolia ® , Xgeva ® ): Fälle von Vaskulitis und Risiko für schwere Hypokalzämien. Dtsch Arztebl 2014; 111: 472-473.
22. Schmitz-Dräger BJ, Weiss C, Ebert T, Dörsam J, Bismarck E: Skeletal-related events in metastatic prostate cancer and the number needed to treat: A critical consideration. Urol Int 2013; 90: 329-333.
23. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate- specific antigen doubling time. J Clin Oncol 2013; 31: 3800-3806.
24. Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F, Huland H, Patel A, Lecouvet F, Caris C, Witjes W: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: Efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 2014, Epub ahead of print.
25. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10: 872-876.
26. European Medicines Agency (EMA): Questions and answers on the outcome of an application for Xgeva to be used in patients with castration-resistant prostate cancer at high risk of spreading to the bones. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/002173/WC500153128.pdf (visited May 1, 2014).
27. Food and Drug Administration (FDA): FDA ODAC Briefing Document. February 8, 2012. BLA 125320/28: Denosumab (Xgeva TM ), Amgen Inc. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Oncologic- DrugsAdvisoryCommittee/UCM290400. pdf (visited May 1, 2014).
28. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O; ALSYMPCA Investigators: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
29. Fuchs B, Trousdale RT, Rock MG: Solitary bony metastasis from renal cell carcinoma: Significance of surgical treatment. Clin Orthop Relat Res 2005; 431: 187-192.
30. Hwang N, Nandra R, Grimer RJ, Carter SR, Tillman RM, Abudu A, Jeys LM: Massive endoprosthetic replacement for bone metastases resulting from renal cell carcinoma: Factors influencing patient survival. Eur J Surg Oncol 2014; 40: 429-434.
31. Saad F, Eastham JA: Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 2010; 37(suppl 1): S38-S44.
32. McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK: Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014, Epub ahead of print.
33. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebrét T, Ribal MJ, Sherif A, van der Heijden AG: Guidelines on muscleinvasive and metastatic bladder cancer. Update 2014. http://www.uroweb.org/gls/pdf/07%20Muscle%20Invasive%20BC-LR.pdf (visited May 1, 2014).
34. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010; 15: 382-389.
35. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J: Guidelines on testicular cancer. Update 2011. http://www.uroweb.org/gls/pdf/11%20 Testicular%20Cancer-LR.pdf (visited May 1, 2014).
36. Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S, Powles T, Chowdhury S: Bone metastases in germ cell tumours: Lessons learnt from a large retrospective study. BJU Int 2013; 112: 176-181.
37. Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C, Honecker F: Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol 2012; 138: 947-952.
38. Froehner M, Aikele P, Beuthien-Baumann B, Kittner T, Oehlschlaeger S, Wirth MP: Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors. Urol Oncol 2007; 25: 201-206.
39. Hakenberg OW, Compérat E, Minhas S, Necchi A, Protzel C, Watkin N: Guidelines on penile cancer. http://www.uroweb.org/gls/pdf/12%20Penile%20Cancer-LR.pdf (visited May 1, 2014).
40. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline ® ): Penile Cancer, Version 1.2014. http://www.nccn.org/professionals/physician-gls/pdf/penile.pdf (visited May 1, 2014).
41. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B: Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008; 19: 420-432.